Articles

Explore how MFN drug pricing and U.S. tariff policies are reshaping global pharmaceutical pricing, supply chains, and innovation. DengYueMed analyzes the impact on multinational pharma strategies, U.S. localization trends, and opportunities for Chinese pharmaceutical companies in a policy-driven global market.
Against the backdrop of an accelerating transformation in the global pharmaceutical industry, policy variables are becoming critical factors influencing drug pricing systems, supply chain structures, and cross-border distribution. As an important bridge connecting Chinese innovation with global medical demand, DengYueMed (Hong Kong DengYue Pharmaceutical Co., Ltd.) continues to monitor international pharmaceutical policy developments and their far-reaching implications for global drug…

The Hospital Capacity Management Solutions Market is experiencing rapid growth due to increasing pressure on healthcare systems to optimize resources and improve patient flow. Valued at over USD 5.3 billion in 2025, the market is projected to reach USD 24.4 billion by 2035, growing at a strong CAGR of 18.5%. These solutions help hospitals efficiently manage beds, staff, equipment, and patient movement in real time, improving operational efficiency and care quality. Growth is driven by rising chronic diseases, advancements in healthcare IT (like AI and predictive analytics), and the need for cost-effective operations. However, challenges such as integration with legacy systems and resistance to workflow changes may hinder adoption.
The global hospital capacity management solutions market…

Explore how evolving pharmaceutical policies accelerate drug approvals, enhance clinical value, and reshape commercialization and supply chain models. Learn how companies adapt to global trends and policy-driven innovation in the pharmaceutical industry.
Against the backdrop of ongoing transformation in the global pharmaceutical industry, policy factors are increasingly becoming a core variable shaping the development of innovative drugs. From reforms in regulatory review and approval systems to the optimization of healthcare reimbursement frameworks, a range of policy tools is reshaping the industry landscape. The growth of innovative drugs is no longer driven solely by technological breakthroughs, but rather by the combined effects of policy direction, capital allocation, and industry col…

A mechanical ventilator is not just another piece of equipment in an intensive care unit. For a clinic, multi-specialty hospital, ICU, or operating room, it is part of a broader clinical infrastructure that affects patient safety, staff workload, workflow stability, and the ability to provide respiratory support across different care scenarios.
How to Choose a Ventilator for a Healthcare Facility: Key Criteria for Safe and Effective Use A mechanical ventilator is not just another piece of equipment in an intensive care unit. For a clinic, multi-specialty hospital, ICU, or operating room, it is part of a broader clinical infrastructure that affects patient safety, staff workload, workflow stability, and the ability to provide respiratory support across different care scenarios. The World He…

Explore the transformation of the global pharmaceutical market driven by innovation, rising healthcare demand, and cross-border drug access. Learn how integrated supply chains and companies like DengYueMed are improving global drug distribution and accessibility.
The global pharmaceutical market is undergoing a major transformation driven by innovation, rising healthcare demand, and improved cross-border drug access. With global spending expected to surpass $2 trillion, the industry is entering a phase where both innovation and accessibility are equally critical. As new therapies emerge and international demand increases, companies like DengYueMed are helping bridge the gap between pharmaceutical innovation and global patient access through integrated supply chain solutions. Key Growth Driv…

Amid an increasingly difficult energy landscape, Steve Ennis, Manufacturing Sector Manager for Aggreko, discusses the potential for battery storage to address grid shortages, spiking energy costs, and sustainability pressures through a number of key applications.
It is hard to imagine a more challenging energy landscape for European pharmaceutical manufacturers at present. Even before recent geopolitical developments caused energy prices to spike, industrial energy costs were, on average, over double that of the United States, and nearly 50% above those in China.[1] Regardless of how the market may shift, the ‘energy trilemma’ that European pharmaceutical manufacturers need to manage to stay competitive remains the same: Resilience – The ability to keep production flowing, even in the face…

Explore how Chinese innovative drugs are reshaping global pharma partnerships in 2026. From record-high upfront payments and antibody innovation to evolving deal structures and multi-therapeutic expansion, discover why global buyers are shifting from price-driven decisions to value-based collaboration.
For global buyers, the evolution of Chinese innovative drugs is no longer merely about “more choices” — it has become a matter of “higher standards.” As a long-term supplier for overseas markets, DengYueMed has observed a clear shift: international partners are increasingly evaluating Chinese innovative drugs based on value rather than price. The data from the first quarter of 2026 illustrates this transformation. 1. Rapid Rise in Upfront Payments: From Volume Growth to Price Upgrade As of Ma…

The global insulin delivery devices market is projected to grow significantly due to rising diabetes prevalence and increasing adoption of advanced insulin delivery technologies. Insulin pens and pumps dominate the market, while smart connected devices are gaining traction. North America leads the market, and Asia-Pacific is expected to witness the fastest growth. Continuous innovation, homecare adoption, and expanding healthcare infrastructure are expected to drive long-term market expansion.
The global insulin delivery devices market is experiencing strong expansion as the prevalence of diabetes continues to rise worldwide. Insulin delivery devices play a crucial role in managing blood glucose levels among diabetic patients by ensuring accurate and convenient insulin administration. These…

Learn how to source medicines from China compliantly with a complete guide to regulatory requirements, cold chain logistics, supplier verification, and digital supply chain strategies. Discover how global healthcare organizations can optimize cross-border pharmaceutical procurement efficiently and securely.
As global healthcare demand continues to grow, China has gradually become an important source of innovative medicines and generic drugs. An increasing number of medical institutions, pharmaceutical distributors, and cross-border procurement companies are paying close attention to how to source medicines from China in a compliant manner. However, due to the complexity of regulatory systems, logistics requirements, and supply chain management, establishing a stable and compliant procuremen…

The nasogastric intubation market is experiencing steady growth driven by rising chronic diseases, aging populations, and increasing demand for enteral feeding solutions. North America dominates due to advanced healthcare infrastructure, while Asia-Pacific is emerging as the fastest-growing region with strong healthcare investments. Key players are focusing on product innovation, antimicrobial tube materials, homecare feeding systems, and smart monitoring technologies to enhance patient safety and comfort. These regional dynamics and technological advancements are expected to accelerate adoption of nasogastric intubation devices globally.
Nasogastric Intubation Market Trends: Homecare Feeding, Aging Population, and Technological Innovation Driving Global Growth The nasogastric intubation ma…

In 2026, China's pharmaceutical industry has evolved from single-asset licensing to complex global healthcare collaborations. Discover how DengYueMed is navigating this transformation, offering regulatory, supply chain, and market entry solutions for Chinese innovative drugs on the global stage.
As a long-term participant deeply engaged in the cross-border pharmaceutical supply chain, DengYueMed has clearly observed through real-world business collaboration that China’s innovative drug globalization in 2026 is no longer characterized by sporadic “project out-licensing,” but rather a systematic paradigm shift toward “global healthcare collaboration.” Transaction structures are becoming increasingly complex, regional rights allocation more refined, and globally coordinated regulatory and supp…

Pharmaceutical innovation exists to improve patient outcomes. Yet between laboratory discovery and patient benefit lies a critical intermediary: conversation. The way clinical evidence is explained, challenged and contextualised in discussions with healthcare professionals (HCPs) plays a meaningful role in how new therapies are understood and adopted in practice. At the same time, the profile of those leading these conversations is changing.
A Broader Talent Model Pharmaceutical commercial models across Europe have shifted towards hybrid engagement structures and greater use of Contract Sales Organisations (CSOs), increasing flexibility in how field teams are deployed.¹ ² Recruitment patterns have diversified in parallel. In the UK, representatives are not required to hold medical, pharma…

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research to late-stage clinical supply without exploding timelines or cost of goods. At the same time, the field is confronting familiar constraints: viral-vector bottlenecks, payload limits, and the risk that DNA elements that are useful for bacterial cloning can become unwanted baggage when the DNA is used as starting material for therapeutics...
Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research to late-stage clinical supply without exploding timelines o…

Workplace attrition threatens operational continuity and clinical trial timelines for life science professionals. The recent shift to remote and decentralized trials presents unique challenges. Fuelled by systemic issues like burnout and depersonalization, and the unique pressures of data-intensive remote work, traditional retention strategies are failing. AI-augmented managed service providers (MSPs) offer a predictive alternative that transforms retention into proactive strategies. Modern health care professionals use deep learning to find hidden patterns and analyze workloads. By scheduling against real-world volatility, they can identify attrition risk and incorporate targeted interventions. Ultimately, they create a more resilient workforce. Organizations must vet, implement and measure the ROI of these strategic partnerships. ...

The global digital stethoscopes market is expected to grow at a compound annual growth rate (CAGR) of approximately 6% during the forecast period, reflecting the ongoing transformation of healthcare delivery systems and the increasing demand for advanced diagnostic technologies.
Market Outlook and Growth Trajectory The global digital stethoscopes market is expected to grow at a compound annual growth rate (CAGR) of approximately 6% during the forecast period, reflecting the ongoing transformation of healthcare delivery systems and the increasing demand for advanced diagnostic technologies. As healthcare providers shift toward data-driven and remote care models, digital stethoscopes are gaining prominence as essential tools for accurate and efficient patient assessment. Get Free Sample Repor…

Safety data overload in pharmacovigilance occurs when drug-safety teams receive extremely large volumes of safety information—such as ICSRs, literature reports, EHR data, and social-media inputs—making it difficult to quickly identify genuine safety signals. Excessive and often low-quality data, including duplicates and inconsistencies, can create noise, increase analyst workload, and delay critical risk-management decisions. This challenge affects signal detection and assessment by causing false positives, alert fatigue, and slower regulatory responses. To address it, organizations are increasingly adopting AI-driven analytics, data standardization, automated deduplication, and advanced signal-detection tools to prioritize meaningful safety insights and ensure efficient pharmacovigilance operations.

Digital Pharmaceutical Supply Chain Management Market Set to Grow at 9% CAGR Amid Rising Demand for Transparency and Drug Traceability
Market Overview The digital pharmaceutical supply chain management market is projected to expand at a compound annual growth rate (CAGR) of approximately 9% between 2025 and 2030, reflecting the growing transition toward technology-driven supply chain ecosystems in the pharmaceutical industry. As pharmaceutical supply networks become more complex and globalized, organizations are increasingly adopting digital technologies to improve visibility, efficiency, and operational resilience. Pharmaceutical companies face mounting pressure to maintain product integrity, ensure regulatory compliance, and quickly respond to fluctuating market demands. Digital supply ch…

Post-Marketing Surveillance (PMS), also known as Phase IV monitoring, plays a critical role in evaluating a drug’s safety, effectiveness, and real-world performance after regulatory approval. While pre-approval clinical trials involve limited and controlled patient populations, PMS monitors medicines in broader and more diverse real-world settings, helping detect rare adverse reactions, long-term risks, and drug interactions that may not appear during earlier trials. Through continuous pharmacovigilance activities such as adverse event reporting, observational studies, and patient registries, PMS provides valuable data that guides regulatory actions, including label updates, boxed warnings, risk-management plans, or even market withdrawal when serious safety concerns arise.
What Is Post‑…

Joint Clinical Assessment JCA is a new EU level clinical evaluation process under Regulation 2021 2282. Mandatory from January 2025 for oncology and advanced therapies, it harmonises comparative clinical assessments across member states. Running in parallel with EMA review, JCA reshapes evidence strategy, trial design, and market access planning across pharma and biotech.
The introduction of Joint Clinical Assessment JCA marks one of the most significant regulatory and market access changes in the European pharmaceutical landscape in decades. Established under the European Health Technology Assessment Regulation Regulation 2021 2282, JCA is reshaping how clinical evidence is assessed across EU member states. For professionals working in regulatory affairs, market access, HEOR, clinical dev…

Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales Organisations (CSOs) - reflects broader expansion across the UK and European pharmaceutical outsourcing market.
Pharmaceutical sales in the UK are undergoing a gradual but meaningful shift in who represents medicines to healthcare professionals. Increasingly, companies are recruiting sales representatives without traditional medical or scientific backgrounds. This evolution, driven in part by changing commercial models and the growth of Contract Sales O…